Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis

Vol.20 No.6

Case Report

Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis

Authors

Masahiro Tada¹ , Takeshi Nakanishi² , Chika Hirata² , Tadashi Okano¹ , Yuko Sugioka¹ , Shigeyuki Wakitani¹ , Hiroaki Nakamura¹ , Tatsuya Koike³

Department of Orthopaedic Surgery, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
Department of Dermatology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
Department of Rheumatosurgery, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan

Received:

10 May 2010

Accepted:

25 June 2010

Published online:

4 August 2010

Full Text

PDF　(member's only)

Abstract

Pyoderma gangrenosum (PG) is characterized by ulcerative skin lesions. Infliximab (IFX) may promote PG healing in patients with inflammatory bowel disease, but whether IFX is effective for treating PG in patients with rheumatoid arthritis (RA) has not reported. We report the case of a 53-year-old woman with PG complicated by RA who was treated using IFX therapy. This case suggests that IFX therapy might offer effective treatment for such patients.

Key words

Infliximab - Pyoderma gangrenosum - Treatment - Rheumatoid arthritis - Tumor necrosis factor α